PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31258693-0	2019	Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.	gemcitabine	100-111	dCMP deaminase	Homo sapiens	135-139	
31258693-13	2019	Inhibition of miR-620 and overexpression of DCTD reversed gemcitabine resistance in MDA-MB-231rGEM1 cells via inducing cell apoptosis and cell growth arrest.	gemcitabine	58-69	dCMP deaminase	Homo sapiens	44-48	
31258693-15	2019	The present results demonstrated that overexpression of miR-620 could contribute to the development of gemcitabine resistance in patients with TNBC via the direct downregulation of DCTD.	gemcitabine	103-114	dCMP deaminase	Homo sapiens	181-185	
28912488-6	2017	As DCTD inhibitor gemcitabine has been proposed as an adjuvant therapy for malignant glioma, our finding also suggests a therapeutic value of gemcitabine for the patients with high expression level of DCTD.	gemcitabine	18-29	dCMP deaminase	Homo sapiens	3-7	
28912488-6	2017	As DCTD inhibitor gemcitabine has been proposed as an adjuvant therapy for malignant glioma, our finding also suggests a therapeutic value of gemcitabine for the patients with high expression level of DCTD.	gemcitabine	18-29	dCMP deaminase	Homo sapiens	201-205	
28912488-6	2017	As DCTD inhibitor gemcitabine has been proposed as an adjuvant therapy for malignant glioma, our finding also suggests a therapeutic value of gemcitabine for the patients with high expression level of DCTD.	gemcitabine	142-153	dCMP deaminase	Homo sapiens	3-7	
28912488-6	2017	As DCTD inhibitor gemcitabine has been proposed as an adjuvant therapy for malignant glioma, our finding also suggests a therapeutic value of gemcitabine for the patients with high expression level of DCTD.	gemcitabine	142-153	dCMP deaminase	Homo sapiens	201-205	
22838949-2	2012	MATERIALS & METHODS: SNPs within nine gemcitabine pathway genes, namely CDA, CMPK, DCK, DCTD, NT5C2, NT5C3, SLC28A1, SLC28A3 and SLC29A1 were analyzed for association with gemcitabine pharmacokinetics.	gemcitabine	42-53	dCMP deaminase	Homo sapiens	92-96	
16708051-4	2006	Polymorphisms of gemcitabine metabolism-related genes of deoxycytidine monophosphate deaminase (DCTD), deoxycytidine kinase (DCK) and ribonucleotide reductase M1 (RRM1) were evaluated using the CEQ8000 Genetic analysis system and GeneDoc software.	gemcitabine	17-28	dCMP deaminase	Homo sapiens	57-94	
16708051-4	2006	Polymorphisms of gemcitabine metabolism-related genes of deoxycytidine monophosphate deaminase (DCTD), deoxycytidine kinase (DCK) and ribonucleotide reductase M1 (RRM1) were evaluated using the CEQ8000 Genetic analysis system and GeneDoc software.	gemcitabine	17-28	dCMP deaminase	Homo sapiens	96-100	
16551864-0	2006	Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.	gemcitabine	0-11	dCMP deaminase	Homo sapiens	53-78	
16551864-2	2006	Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD).	gemcitabine	0-11	dCMP deaminase	Homo sapiens	106-131	
16551864-2	2006	Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD).	gemcitabine	0-11	dCMP deaminase	Homo sapiens	133-137